ArticleThe Journal of international medical research2021
Mutations in domain V of
Article in The Journal of international medical research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 20 citations in OpenAlex.
- Clinical characteristics and associated factors of macrolide-resistant mycoplasma pneumoniae pneumonia in children: a systematic review and meta-analysis.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025Pooled it
- Association between point mutations of macrolide-resistantFrontiers in pharmacology · 2025Pooled it
- Association of doxycycline treatment with time to first documented MP-RNA negative conversion in pediatric Mycoplasma pneumoniae pneumonia: a retrospective cohort study.Italian journal of pediatrics · 2026Article
- Article
- Doxycycline for Macrolide-ResistantInfection and drug resistance · 2026Review
- Association analysis of Mycoplasma pneumoniae 23S rRNA gene mutation with refractory Mycoplasma pneumoniae pneumonia in children.PloS one · 2026Article
- Macrolide-resistantFrontiers in pediatrics · 2026Article
- From genes to clinical application: a circulating four-gene signature for early diagnosis model of refractoryFrontiers in cellular and infection microbiology · 2026Article
- Doxycycline vs levofloxacin for macrolide-unresponsive Mycoplasma pneumoniae pneumonia in children: a real-world study from China.Italian journal of pediatrics · 2025Observational
- Comprehensive study of community acquiredWorld journal of clinical pediatrics · 2025Article
- Clinical features associated with macrolides resistance of Mycoplasma pneumoniae pneumonia in children: a single-center analysis.BMC infectious diseases · 2025Article
- Navigating the outbreak: a comprehensive analysis of pediatricMicrobiology spectrum · 2025Article
- Epidemiological characteristics of severe community-acquired pneumonia in children admitted to two tertiary hospitals in Shihezi, Xinjiang Region, China in 2023: a cross-sectional analysis.Journal of thoracic disease · 2024Article
- Macrolide resistance ofEpidemiology and infection · 2024Article
- [Macrolide-resistant Mycoplasma pneumoniae: Do we know the situation in Europe?]Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2023Review
- Molecular beacon based real-time PCR p1 gene genotyping, macrolide resistance mutation detection and clinical characteristics analysis of Mycoplasma pneumoniae infections in children.BMC infectious diseases · 2022Article
- Update on the Epidemiology of Macrolide-ResistantInfectious disease reports · 2021Review
- Increased Total Serum Immunoglobulin E Is Likely to Cause Complications ofFrontiers in cellular and infection microbiology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the prevalence of mutations in domain V of
methodsDomain V of 23S rRNA was sequenced in MP strains collected from children diagnosed with MPP in Nanjing. Clinical and laboratory data were obtained.
resultsAmong the 276 MP strains, 255 (92.39%) harbored mutations, primarily A2063G in domain V of MP 23S rRNA. When children were stratified according to the presence or absence of mutations, no significant differences were found in sex, age, the MP DNA load at enrollment, lymphocyte counts, pulmonary complications, immunomodulator levels, fever duration, the duration of fever after macrolide therapy, and hospital stay. The prevalence of refractory MPP in the two groups was similar. Children with refractory MPP exhibited higher MP DNA loads than those with non-refractory MPP.
conclusionsDespite the high prevalence of the A2063G mutation in domain V of MP 23S rRNA, mutations were not associated with the clinical characteristics of MPP. The MP DNA load significantly differed between refractory and non-refractory MPP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.